Toronto, Canada & Bengaluru, India, April 21, 2026

In a significant advancement for global biosimilars and bone health therapeutics, Biocon Limited has received Health Canada approval for its denosumab biosimilars Bosaya™ and Vevzuo™, marking a major milestone in expanding access to affordable biologic treatments. These approvals, granted as a Notice of Compliance (NOC), position Biocon to address the needs of millions of patients suffering from osteoporosis and cancer-related bone complications, reinforcing its leadership in the biosimilars market. The newly approved therapies are biosimilars to Prolia® and Xgeva®, widely used treatments for bone-related disorders, and are expected to significantly improve treatment accessibility and healthcare affordability in Canada.

Bosaya and Vevzuo Expand Access to Critical Bone Therapies

The approval of Bosaya™ (60 mg/mL) and Vevzuo™ (120 mg/1.7 mL) provides clinicians with new, cost-effective options for managing osteoporosis and skeletal-related complications of cancer. Bosaya is indicated for patients at high risk of fractures, including postmenopausal women, men with osteoporosis, and individuals undergoing hormone-related cancer therapies, while Vevzuo is approved for preventing skeletal-related events in patients with bone metastases and multiple myeloma, as well as treating giant cell tumor of bone and hypercalcemia of malignancy.

These conditions represent a substantial burden on healthcare systems, with osteoporosis alone affecting millions globally, often leading to fractures, reduced mobility, and diminished quality of life. By offering high-quality biosimilars with no clinically meaningful differences in safety, efficacy, or quality, Biocon is enabling broader patient access to life-saving biologic therapies.

Denosumab Mechanism Enhances Bone Strength and Protection

Advertisement

cGxPJobs Banner

Both Bosaya and Vevzuo are based on denosumab, a human monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a key protein involved in bone resorption. By inhibiting RANKL, these therapies prevent the formation and activity of osteoclasts, the cells responsible for bone breakdown, thereby increasing bone density and reducing fracture risk.

This mechanism is particularly important in patients with cancer-related bone disease, where tumor-induced bone destruction can lead to severe complications. The approval is supported by a comprehensive dataset, including analytical, nonclinical, and clinical studies, demonstrating biosimilarity to the reference products without compromising clinical outcomes.

Strategic Growth in Global Biosimilars Market

This regulatory success highlights Biocon’s continued expansion in the global biosimilars landscape, particularly in advanced markets such as Canada. With a strong portfolio of 12 commercialized biosimilars and over 20 pipeline assets, the company is focused on delivering affordable, high-quality biologics across key therapeutic areas including oncology, immunology, and bone health.

The approval of Bosaya and Vevzuo aligns with Biocon’s mission to address high unmet medical needs while ensuring sustainable healthcare solutions. Furthermore, the growing adoption of biosimilars is expected to play a crucial role in reducing healthcare costs and improving patient access worldwide, making this approval a strategically important development for both Biocon and the broader pharmaceutical industry.

Overall, Biocon’s Health Canada approval for its denosumab biosimilars marks a pivotal step in advancing accessible and affordable biologic therapies, offering new hope for patients with osteoporosis and cancer-related bone diseases. By combining scientific excellence, regulatory strength, and global reach, Biocon continues to drive innovation and expand access to life-changing treatments across international markets.

Source: Biocon press release